ERBB2 and breast carcinoma: Elevated PEAK1 expression across all breast cancer subtypes predicted a significant, though slight, increase in RFS (Fig. 1a), while elevated PEAK1 expression in HER2-positive breast cancers correlated with decreased RFS suggesting a role for PEAK1 in this more aggressive breast cancer subtype (Fig. 1b).